Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.3%

Dec 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: greedsgd_2000 who wrote (1767)	9/29/2000 4:54:10 PM
From: keokalani'nui	Read Replies (1) of 52153

greedsgd <<1. Wall St Journal front page-left- Sept 28 article referring to small study at Mass General Hospital - with the conclusion that an Immune based strategy may now be possible against HIV. The article fails to mention HEPH in any way, which seems odd as they are probably one of the few focusing on this immune based approach.>> If its the article I remember, the reported approach depends on virtually immediate shock treatment with existing therapies after infection, then total withdrawal. HEPH's product is designed to tilt the immune system back in favor of the previously depleted helper T-cells using a novel molecule. So the two are related only in disease, but not otherwise. The new hires are interesting. Thank you. I am trying to read the poster from the So African conference (I've never seen a smaller font) and if I think of anything interesting I'll post over at HEPH. Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next